Indivior Pharmaceuticals, Inc INDV
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-06-12 |
| Shares Out. | 121,000,000 |
| Website | indivior.com/ ↗ |
| Phone | 18043791090 |
| Employees | 838 |
| Revenue | $317.0M |
| Gross Profit | $277.0M |
| Net Income | $89.0M |
| Free Cash Flow | -$193.0M |
| Total Assets | $1.20B |
| Total Liabilities | $1.34B |
| Equity | -$144.0M |
About Indivior Pharmaceuticals, Inc
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals, Inc is a publicly traded company under the ticker symbol INDV on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)